Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
University Hospitals Coventry and Warwickshire NHS Trust
UMC Utrecht
University Health Network, Toronto
University of Aarhus
Mayo Clinic
M.D. Anderson Cancer Center
University of Washington
Sun Yat-sen University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
University of California, Irvine
Thomas Jefferson University
Vanderbilt-Ingram Cancer Center
Mayo Clinic
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sichuan University
Maastricht Radiation Oncology
University Medical Center Groningen
Humanetics Corporation
Swiss Cancer Institute
Sichuan University
Spanish Lung Cancer Group
Nanfang Hospital, Southern Medical University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Amsterdam UMC, location VUmc
Swiss Cancer Institute
Fox Chase Cancer Center
University of Pittsburgh
SCRI Development Innovations, LLC
Fox Chase Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Spectrum Pharmaceuticals, Inc